166 related articles for article (PubMed ID: 38063420)
1. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
[TBL] [Abstract][Full Text] [Related]
2. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
3. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
Wang Z; Zhang A; Xu Z; Wang N; Zhang J; Meng J; Dong S; Ma J; Hu Y; Ouyang J; Chen Z; An Q; Cheng X; Wu R
Br J Haematol; 2024 May; 204(5):1958-1965. PubMed ID: 38362793
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
[TBL] [Abstract][Full Text] [Related]
7. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
[TBL] [Abstract][Full Text] [Related]
9. Avatrombopag for the treatment of immune thrombocytopenia.
Długosz-Danecka M; Zdziarska J; Jurczak W
Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
Al-Samkari H; Nagalla S
Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of avatrombopag for the treatment of thrombocytopenia.
Virk ZM; Kuter DJ; Al-Samkari H
Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
[No Abstract] [Full Text] [Related]
12. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Bussel JB; Kuter DJ; Aledort LM; Kessler CM; Cuker A; Pendergrass KB; Tang S; McIntosh J
Blood; 2014 Jun; 123(25):3887-94. PubMed ID: 24802775
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
[TBL] [Abstract][Full Text] [Related]
14. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
[No Abstract] [Full Text] [Related]
15. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
16. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Zeng Y; Duan X; Xu J; Ni X
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
[TBL] [Abstract][Full Text] [Related]
17. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
[No Abstract] [Full Text] [Related]
18. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.
Snell Taylor SJ; Nielson CM; Breskin A; Saul B; Yu Y; Alam N; Eisen M; Hippenmeyer J; Janssens A; Kozak T; Papadaki HA; Selleslag D; Viallard JF; Feistritzer C; Kaiafa G; Kelsh M; Kilpatrick K; Brookhart MA; McGrath LJ
Adv Ther; 2021 May; 38(5):2673-2688. PubMed ID: 33866516
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]